Literature DB >> 15520652

Formulary conversion programs: the need for patient-specific risk assessment.

Sonal Singh1, Rakesh Shrivastava, Vijay Das.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15520652      PMCID: PMC1435601     

Source DB:  PubMed          Journal:  MedGenMed        ISSN: 1531-0132


× No keyword cloud information.
  5 in total

Review 1.  Drug interactions and the statins.

Authors:  R J Herman
Journal:  CMAJ       Date:  1999-11-16       Impact factor: 8.262

Review 2.  Risk for myopathy with statin therapy in high-risk patients.

Authors:  Christie M Ballantyne; Alberto Corsini; Michael H Davidson; Hallvard Holdaas; Terry A Jacobson; Eran Leitersdorf; Winfried März; John P D Reckless; Evan A Stein
Journal:  Arch Intern Med       Date:  2003-03-10

3.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

4.  Lipid-lowering efficacy, safety, and costs of a large-scale therapeutic statin formulary conversion program.

Authors:  A J Taylor; K Grace; J Swiecki; R Hyatt; H Gibbs; M Sheikh; P G O'Malley; S P Lowenthal; M West; J Spain; K Maneval; D L Jones
Journal:  Pharmacotherapy       Date:  2001-09       Impact factor: 4.705

Review 5.  3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and rhabdomyolysis: considerations in the renal failure patient.

Authors:  Domenic A Sica; Todd W B Gehr
Journal:  Curr Opin Nephrol Hypertens       Date:  2002-03       Impact factor: 2.894

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.